Showing results (1301-1310 of 1,358) with videos related to

Sort By:
Pageof 136
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 12, 2019
First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid TumorsGerald S Falchook, Razelle Kurzrock, Hesham M Amin, et al.
The Journal of Investigative Dermatology|February 3, 2018
Mycophenolate Mofetil Treatment of Systemic Sclerosis Reduces Myeloid Cell Numbers and Attenuates the Inflammatory Gene Signature in SkinMonique Hinchcliff, Diana M Toledo, Jaclyn N Taroni, et al.
Oncotarget|November 7, 2014
Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumabGerald S Falchook, Jennifer J Wheler, Aung Naing, et al.
International Journal of Radiation Oncology, Biology, Physics|July 28, 2025
Associations Between G8 Geriatric Screening Score, Charlson Comorbidity Index, AI-Based Age Phenotype, and Overall Survival in Older Adults With Stage I-II Non-Small Cell Lung CancerLeah L Thompson, Priya M Amin, Sanjana Shah, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2015
Integrative molecular profiling of routine clinical prostate cancer specimensC S Grasso, A K Cani, D H Hovelson, et al.
Journal of Immunotherapy and Precision Oncology|November 11, 2024
Circulating Galectin-3: A Prognostic Biomarker in Hepatocellular CarcinomaShadi Chamseddine, Betul Gok Yavuz, Yehia I Mohamed, et al.
Oncology|July 19, 2023
Clinical and Prognostic Biomarker Value of Blood-Circulating Inflammatory Cytokines in Hepatocellular CarcinomaShadi Chamseddine, Yehia I Mohamed, Sunyoung S Lee, et al.
Molecular Cancer Research : MCR|January 17, 2015
Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes TumorsAndi K Cani, Daniel H Hovelson, Andrew S McDaniel, et al.
The New England Journal of Medicine|November 12, 2013
Abatacept in B7-1-positive proteinuric kidney diseaseChih-Chuan Yu, Alessia Fornoni, Astrid Weins, et al.
Oncotarget|December 6, 2022
Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patientsYehia I Mohamed, Dan G Duda, Muhammad O Awiwi, et al.
Pageof 136